Vytrus Biotech, S.A. (BME:VYT)
Spain · Delayed Price · Currency is EUR 17.00
+0.60 (3.66%)
At close: Jul 17, 2026
Vytrus Biotech Revenue
In the year 2025, Vytrus Biotech had annual revenue of 8.37M EUR with 65.95% growth. Vytrus Biotech had revenue of 3.99M in the half year ending December 31, 2025, with 123.79% growth.
Revenue
8.37M
Revenue Growth
+65.95%
P/S Ratio
13.18
Revenue / Employee
220.28K
Employees
44
Market Cap
127.78M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 8.37M | 3.33M | 65.95% |
| Dec 31, 2024 | 5.04M | 1.31M | 35.00% |
| Dec 31, 2023 | 3.74M | 54.51K | 1.48% |
| Dec 31, 2022 | 3.68M | 877.98K | 31.31% |
| Dec 31, 2021 | 2.80M | 1.10M | 64.49% |
| Dec 31, 2020 | 1.70M | 482.98K | 39.53% |
| Dec 31, 2019 | 1.22M | 334.11K | 37.63% |
| Dec 31, 2018 | 887.81K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Grifols | 7.44B |
| Almirall | 1.12B |
| Laboratorios Farmaceuticos Rovi | 741.09M |
| Faes Farma | 674.06M |
| Laboratorio Reig Jofre | 335.01M |
| Clínica Baviera | 304.91M |
| Prim, S.A. | 251.89M |
| Atrys Health | 144.31M |